iTeos Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de iTeos Therapeutics' es Michel Detheux , nombrado en Aug 2011, tiene una permanencia de 12.67 años. compensación anual total es $10.51M, compuesta por 5.3% salario y 94.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.063% de las acciones de la empresa, por valor de $244.42K. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 4.1 años, respectivamente.
Información clave
Michel Detheux
Chief Executive Officer (CEO)
US$5.8m
Compensación total
| Porcentaje del salario del CEO | 10.0% |
| Permanencia del CEO | 12.8yrs |
| Participación del CEO | 0.06% |
| Permanencia media de la dirección | 4yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 25
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Jan 10Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%
May 13Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding
Mar 21The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically
Aug 12iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04
Aug 10iTeos Therapeutics: Too Many Unknowns
Jul 27News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts
May 11Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic
Nov 25We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth
Aug 24iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share
Aug 15GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler
Jun 15We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth
Feb 07Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?
Dec 16
iTeos Therapeutics EPS misses by $0.11
Nov 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$579k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | US$12m |
| Dec 31 2022 | US$11m | US$556k | US$97m |
| Sep 30 2022 | n/a | n/a | US$261m |
| Jun 30 2022 | n/a | n/a | US$330m |
| Mar 31 2022 | n/a | n/a | US$298m |
| Dec 31 2021 | US$6m | US$525k | US$215m |
| Sep 30 2021 | n/a | n/a | US$15m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$17m | US$463k | -US$43m |
| Sep 30 2020 | n/a | n/a | -US$35m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$28m |
| Dec 31 2019 | US$2m | US$460k | -US$27m |
Compensación vs. Mercado: La compensación total de Michel($USD10.51M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Michel ha sido consistente con los resultados de la empresa en el último año.
CEO
Michel Detheux (57 yo)
12.8yrs
Permanencia
US$5,767,774
Compensación
Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 12.8yrs | US$5.77m | 0.057% $ 346.6k | |
| Chief Financial Officer | 4yrs | US$2.72m | 0.052% $ 316.7k | |
| Chief Operating Officer | 4.8yrs | US$2.80m | 0.25% $ 1.5m | |
| Chief Scientific Officer | 2.4yrs | sin datos | sin datos | |
| Executive Vice President of Legal | 1.4yrs | sin datos | sin datos | |
| Executive Vice President of Human Resources | 4.4yrs | sin datos | sin datos | |
| Interim Chief Medical Officer | 1.4yrs | sin datos | sin datos |
4.0yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ITOS se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 12.4yrs | US$5.77m | 0.057% $ 346.6k | |
| Independent Director | 4yrs | US$317.52k | 0% $ 0 | |
| Independent Chairman of the Board | 6yrs | US$416.42k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$253.52k | 0% $ 0 | |
| Independent Director | 6yrs | US$303.52k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.2yrs | US$305.02k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$308.27k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
4.3yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de ITOS se considera experimentada (4.1 años de antigüedad promedio).